A new atherosclerotic lesion probe based on hydrophobically modified chitosan nanoparticles functionalized by the atherosclerotic plaque targeted peptides

Kyeongsoon Park, Hai Yan Hong, Hyun Jeong Moon, Byung Heon Lee, In-San Kim, Ick Chan Kwon, Kyehan Rhee

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

We developed a new imaging probe for atherosclerotic lesion imaging by chemically conjugating an atherosclerotic plaque-homing peptide (termed the AP peptide) to hydrophobically modified glycol chitosan (HGC) nanoparticles. The AP peptide was previously discovered by using an in vivo phage display screening method. HGC nanoparticles were labeled with the near-infrared (NIR) fluorophore Cy5.5, yielding nanoparticles 314 nm in diameter. The binding characteristics of nanoparticles to cytokine (TNF-α)-activated bovine aortic endothelial cells (BAECs) were studied in vitro under static conditions and in a dynamic flow environment. AP-tagged HGC-Cy5.5 nanoparticles (100 μg/ml, 2 h incubation) bound more avidly to TNF-α-activated BAECs than to unactivated BAECs. Nanoparticles were mostly located in the membranes of BAECs, although some were taken up by the cells and were visible in the cytoplasm, suggesting that the AP peptides in HGC nanoparticles retained target selectivity for activated BAECs. Binding selectivity of AP-tagged HGC-Cy5.5 nanoparticles was also studied in vivo. NIR fluorescence imaging demonstrated that AP-tagged HGC-Cy5.5 nanoparticles bound better to atherosclerotic lesions in a low-density lipoprotein receptor-deficient (Ldlr-/-) atherosclerotic mouse than to such lesions in a normal mouse. These results suggest that the newly designed AP-tagged HGC-Cy5.5 nanoparticles may be useful for atherosclerotic lesion imaging, and may also be employed to elucidate pathophysiological changes, at the molecular level, on atherosclerotic endothelium.

Original languageEnglish
Pages (from-to)217-223
Number of pages7
JournalJournal of Controlled Release
Volume128
Issue number3
DOIs
Publication statusPublished - 2008 Jun 24
Externally publishedYes

Fingerprint

Chitosan
Atherosclerotic Plaques
Nanoparticles
Peptides
Endothelial Cells
LDL Receptors
Optical Imaging
glycol-chitosan
Bacteriophages
Endothelium
Cytoplasm
CY5.5 cyanine dye
Cytokines
Membranes

Keywords

  • Atherosclerosis
  • Atherosclerotic plaque-homing peptide
  • Hydrophobically modified glycol chitosan nanoparticle
  • NIR optical imaging

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

A new atherosclerotic lesion probe based on hydrophobically modified chitosan nanoparticles functionalized by the atherosclerotic plaque targeted peptides. / Park, Kyeongsoon; Hong, Hai Yan; Moon, Hyun Jeong; Lee, Byung Heon; Kim, In-San; Kwon, Ick Chan; Rhee, Kyehan.

In: Journal of Controlled Release, Vol. 128, No. 3, 24.06.2008, p. 217-223.

Research output: Contribution to journalArticle

Park, Kyeongsoon ; Hong, Hai Yan ; Moon, Hyun Jeong ; Lee, Byung Heon ; Kim, In-San ; Kwon, Ick Chan ; Rhee, Kyehan. / A new atherosclerotic lesion probe based on hydrophobically modified chitosan nanoparticles functionalized by the atherosclerotic plaque targeted peptides. In: Journal of Controlled Release. 2008 ; Vol. 128, No. 3. pp. 217-223.
@article{80c8f826a97c411abd100cf0f4fadf41,
title = "A new atherosclerotic lesion probe based on hydrophobically modified chitosan nanoparticles functionalized by the atherosclerotic plaque targeted peptides",
abstract = "We developed a new imaging probe for atherosclerotic lesion imaging by chemically conjugating an atherosclerotic plaque-homing peptide (termed the AP peptide) to hydrophobically modified glycol chitosan (HGC) nanoparticles. The AP peptide was previously discovered by using an in vivo phage display screening method. HGC nanoparticles were labeled with the near-infrared (NIR) fluorophore Cy5.5, yielding nanoparticles 314 nm in diameter. The binding characteristics of nanoparticles to cytokine (TNF-α)-activated bovine aortic endothelial cells (BAECs) were studied in vitro under static conditions and in a dynamic flow environment. AP-tagged HGC-Cy5.5 nanoparticles (100 μg/ml, 2 h incubation) bound more avidly to TNF-α-activated BAECs than to unactivated BAECs. Nanoparticles were mostly located in the membranes of BAECs, although some were taken up by the cells and were visible in the cytoplasm, suggesting that the AP peptides in HGC nanoparticles retained target selectivity for activated BAECs. Binding selectivity of AP-tagged HGC-Cy5.5 nanoparticles was also studied in vivo. NIR fluorescence imaging demonstrated that AP-tagged HGC-Cy5.5 nanoparticles bound better to atherosclerotic lesions in a low-density lipoprotein receptor-deficient (Ldlr-/-) atherosclerotic mouse than to such lesions in a normal mouse. These results suggest that the newly designed AP-tagged HGC-Cy5.5 nanoparticles may be useful for atherosclerotic lesion imaging, and may also be employed to elucidate pathophysiological changes, at the molecular level, on atherosclerotic endothelium.",
keywords = "Atherosclerosis, Atherosclerotic plaque-homing peptide, Hydrophobically modified glycol chitosan nanoparticle, NIR optical imaging",
author = "Kyeongsoon Park and Hong, {Hai Yan} and Moon, {Hyun Jeong} and Lee, {Byung Heon} and In-San Kim and Kwon, {Ick Chan} and Kyehan Rhee",
year = "2008",
month = "6",
day = "24",
doi = "10.1016/j.jconrel.2008.03.019",
language = "English",
volume = "128",
pages = "217--223",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - A new atherosclerotic lesion probe based on hydrophobically modified chitosan nanoparticles functionalized by the atherosclerotic plaque targeted peptides

AU - Park, Kyeongsoon

AU - Hong, Hai Yan

AU - Moon, Hyun Jeong

AU - Lee, Byung Heon

AU - Kim, In-San

AU - Kwon, Ick Chan

AU - Rhee, Kyehan

PY - 2008/6/24

Y1 - 2008/6/24

N2 - We developed a new imaging probe for atherosclerotic lesion imaging by chemically conjugating an atherosclerotic plaque-homing peptide (termed the AP peptide) to hydrophobically modified glycol chitosan (HGC) nanoparticles. The AP peptide was previously discovered by using an in vivo phage display screening method. HGC nanoparticles were labeled with the near-infrared (NIR) fluorophore Cy5.5, yielding nanoparticles 314 nm in diameter. The binding characteristics of nanoparticles to cytokine (TNF-α)-activated bovine aortic endothelial cells (BAECs) were studied in vitro under static conditions and in a dynamic flow environment. AP-tagged HGC-Cy5.5 nanoparticles (100 μg/ml, 2 h incubation) bound more avidly to TNF-α-activated BAECs than to unactivated BAECs. Nanoparticles were mostly located in the membranes of BAECs, although some were taken up by the cells and were visible in the cytoplasm, suggesting that the AP peptides in HGC nanoparticles retained target selectivity for activated BAECs. Binding selectivity of AP-tagged HGC-Cy5.5 nanoparticles was also studied in vivo. NIR fluorescence imaging demonstrated that AP-tagged HGC-Cy5.5 nanoparticles bound better to atherosclerotic lesions in a low-density lipoprotein receptor-deficient (Ldlr-/-) atherosclerotic mouse than to such lesions in a normal mouse. These results suggest that the newly designed AP-tagged HGC-Cy5.5 nanoparticles may be useful for atherosclerotic lesion imaging, and may also be employed to elucidate pathophysiological changes, at the molecular level, on atherosclerotic endothelium.

AB - We developed a new imaging probe for atherosclerotic lesion imaging by chemically conjugating an atherosclerotic plaque-homing peptide (termed the AP peptide) to hydrophobically modified glycol chitosan (HGC) nanoparticles. The AP peptide was previously discovered by using an in vivo phage display screening method. HGC nanoparticles were labeled with the near-infrared (NIR) fluorophore Cy5.5, yielding nanoparticles 314 nm in diameter. The binding characteristics of nanoparticles to cytokine (TNF-α)-activated bovine aortic endothelial cells (BAECs) were studied in vitro under static conditions and in a dynamic flow environment. AP-tagged HGC-Cy5.5 nanoparticles (100 μg/ml, 2 h incubation) bound more avidly to TNF-α-activated BAECs than to unactivated BAECs. Nanoparticles were mostly located in the membranes of BAECs, although some were taken up by the cells and were visible in the cytoplasm, suggesting that the AP peptides in HGC nanoparticles retained target selectivity for activated BAECs. Binding selectivity of AP-tagged HGC-Cy5.5 nanoparticles was also studied in vivo. NIR fluorescence imaging demonstrated that AP-tagged HGC-Cy5.5 nanoparticles bound better to atherosclerotic lesions in a low-density lipoprotein receptor-deficient (Ldlr-/-) atherosclerotic mouse than to such lesions in a normal mouse. These results suggest that the newly designed AP-tagged HGC-Cy5.5 nanoparticles may be useful for atherosclerotic lesion imaging, and may also be employed to elucidate pathophysiological changes, at the molecular level, on atherosclerotic endothelium.

KW - Atherosclerosis

KW - Atherosclerotic plaque-homing peptide

KW - Hydrophobically modified glycol chitosan nanoparticle

KW - NIR optical imaging

UR - http://www.scopus.com/inward/record.url?scp=44649196487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44649196487&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2008.03.019

DO - 10.1016/j.jconrel.2008.03.019

M3 - Article

C2 - 18457896

AN - SCOPUS:44649196487

VL - 128

SP - 217

EP - 223

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 3

ER -